Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.49 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.42 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8071622 | 0.98 | CYP1A2 (0.47) | CYP1A2CYSLTR1CYSLTR2PDE10AGPBAR1 | |
| Bromide SCHEMBL4485285 | 0.96 | CYP1A2 (0.49) | CYP1A2CYSLTR1CYSLTR2PDE10AGPBAR1 | |
| Hydrochloric Acid SCHEMBL7512828 | 0.81 | ALDH1A1 (0.41) | CYP1A2CYSLTR1CYSLTR2PDE10AHIF1A | |
| Bromide SCHEMBL7086028 | 0.79 | NR4A2 (0.40) | CYP1A2PDE10A | |
| Hydrochloric Acid SCHEMBL9033991 | 0.79 | CYSLTR1 (0.65) | CYSLTR1CYSLTR2PDE10AGPBAR1 | |
| Hydrochloric Acid SCHEMBL7450279 | 0.78 | KDM4E (0.42) | PDE10AHIF1A | |
| Bromide SCHEMBL7246358 | 0.76 | SNCA (0.34) | CYP1A2CYSLTR1CYSLTR2PDE10AHIF1A | |
| Hydrochloric Acid SCHEMBL8124320 | 0.76 | HIF1A (0.33) | HIF1A | |
| SCHEMBL31570744 | 0.74 | CYSLTR2 (0.51) | CYP1A2CYSLTR1CYSLTR2GPBAR1KDM1A | |
| SCHEMBL31570746 | 0.74 | CYSLTR2 (0.51) | CYP1A2CYSLTR1CYSLTR2GPBAR1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066627-B1 | NOVEL MINOR GROOVE BINDERS | UNIV STRATHCLYDE (GB) | 2013-10-23 | — | — | EP | disclosed |
| US-8012967-B2 | Minor groove binders | UNIVERSITY OF STRATHCLYDE (GB) | 2011-09-06 | — | — | US | disclosed |
| US-20100016311-A1 | NOVEL MINOR GROOVE BINDERS | UNIVERSITY OF STRATHCLYDE (GB) | 2010-01-21 | — | — | US | disclosed |
| EP-2066627-A1 | NOVEL MINOR GROOVE BINDERS | The University of Strathclyde (GB) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008038018-A1 | NOVEL MINOR GROOVE BINDERS | UNIVERSITY OF STRATHCLYDE (GB) | 2008-04-03 | — | — | WO | disclosed |
| US-7005440-B1 | Therapeutic uses of tri-aryl acid derivatives | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2006-02-28 | — | — | US | disclosed |
| EP-1177176-A1 | TRI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS | Aventis Pharma Deutschland GmbH (DE) | 2002-02-06 | — | — | EP | disclosed |
| EP-0905134-B1 | Piperidine derivatives as LTD4 and H1 antagonists | KOWA CO (JP) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000064876-A1 | TRI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-02 | — | — | WO | disclosed |
| US-6107308-A | ANTIHISTAMINE; LEUTRIENE ANTAGONIST | KOWA CO., LTD. (JP) | 2000-08-22 | — | — | US | disclosed |
| US-6066672-A | OF GIVEN FORMULA COMPRISING A SUBSTITUTED AMINOALKYL(AMIDO OR ALKYLAMINO)ALKYL(AMIDO OR ALKYLAMINO)ALKYL(ALKENE, ALKYL OR ALKOXYCARBONYL) | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2000-05-23 | — | — | US | disclosed |
| EP-0469833-B1 | N-Benzyl-Indoles, processes for their preparation and pharmaceutical compositions containing them | LILLY CO ELI (GB) | 1999-09-08 | — | — | EP | disclosed |
| EP-0905134-A1 | Piperidine derivatives as LTD4 and H1 antagonists | KOWA COMPANY, LTD. (JP) | 1999-03-31 | — | — | EP | disclosed |
| EP-0882699-A1 | AMINO COMPOUNDS AND ANGIOTENSIN IV RECEPTOR AGONISTS | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1998-12-09 | — | — | EP | disclosed |
| US-5281593-A | Pharmaceuticals | LILLY INDUSTRIES LIMITED (GB) | 1994-01-25 | — | — | US | disclosed |
| EP-0469833-A1 | N-Benzyl-Indoles, processes for their preparation and pharmaceutical compositions containing them | LILLY INDUSTRIES LIMITED (GB) | 1992-02-05 | — | — | EP | disclosed |
| EP-0150984-B1 | 6-(SUBSTITUTED) METHYLENEPENICILLANIC AND 6-(SUBSTITUTED) HYDROXYMETHYLPENICILLANIC ACIDS AND DERIVATIVES THEREOF | PFIZER INC. (US) | 1991-09-11 | — | — | EP | disclosed |
| US-5015473-A | Beta-lactamase inhibitors | PFIZER INC. (US) | 1991-05-14 | — | — | US | disclosed |
| US-4826833-A | ANTIBIOTICS | PFIZER INC. (US) | 1989-05-02 | — | — | US | disclosed |
| EP-0150984-A2 | 6-(Substituted) methylenepenicillanic and 6-(substituted) hydroxymethylpenicillanic acids and derivatives thereof | PFIZER INC. (US) | 1985-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016311-A1 | NOVEL MINOR GROOVE BINDERS | TOP2B, DNA2, CTCF | CYP1A2 1546/4885CYSLTR1 4358/4885CYSLTR2 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.